After Reaching Another 52-Week High, Valeant Pharmaceuticals Intl Inc. Should Still Be Avoided at All Costs!

Shares of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) should still be avoided at all costs.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Over the past few days, shares of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) have hit a 52-week high in excess of $28.50, as the company has announced the original offering of US$1 billion in debt, which was then extended to US$1.5 billion. Essentially, debt holders are giving the company a vote of confidence until the maturity of the debt in 2025.

Although this move pushed out the debt maturity schedule for the company, the reality is that the interest rate now being paid to borrow money and maintain operations is an astonishing 9%! The negative aspect of this situation is that the company will be retiring debt with costs between 5% and 7%. Interest costs will continue to increase for two key reasons: the higher-risk profile of the company, and the overall increase in interest rates, which is moving through the general markets. After considering the numbers for the first three quarters of the 2017 fiscal year, I have both good and bad news for the company and investors.

The good news is that the interest expense through the first three quarters of the year has stabilized at US$1.392 billion for 2017 in comparison to US$1.367 billion for the 2016 fiscal year. The bad news is that the interest expense on a year-over-year basis has stabilized just as revenues have declined from US$7.271 billion to US$6.561 billion. The percentage of revenues that are being spent on the servicing of debt has increased from 18.8% to an astonishing 21.2% and is expected to increase even more over the next fiscal year. Over the next year, revenues are expected to decline amid lower revenues.

Although the company has successfully turned a profit in two of the past four quarters, investors need to look behind the curtain and consider what is really happening with the company’s cash flow situation. Over the first three quarters of the year, the company has generated cash from operations (CFO) of US$1.712 billion in comparison to US$1.575 for the same period in fiscal 2016. The interest costs are now taking up more than 80% of CFO — a very dangerous game, indeed.

As is sometimes the case, a highly levered company that has faced the realities of bankruptcy can sometimes provide investors incredible returns, as the leverage employed becomes substantial, and expectations are easily surpassed. In the case of Valeant, many shareholders have come to their senses and sold off at a large loss throughout the year, while those currently holding the security have most probably bought at substantially lower prices, which makes the name one of the least-hated on the street — how times have changed!

With time working against it, investors may be wise to take what they can get, while the house is still standing.

Good luck with this name for 2018!

Should you invest $1,000 in Bausch Health Companies right now?

Before you buy stock in Bausch Health Companies, consider this:

The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and Bausch Health Companies wasn’t one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years.

Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the “eBay of Latin America” at the time of our recommendation, you’d have $20,697.16!*

Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 29 percentage points since 2013*.

See the Top Stocks * Returns as of 3/20/25

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor RyanGoldsman has no position in any of the stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

Confidently Navigate Market Volatility: Claim Your Free Report!

Feeling uneasy about the ups and downs of the stock market lately? You’re not alone. At The Motley Fool Canada, we get it — and we’re here to help. We’ve crafted an essential guide designed to help you through these uncertain times: "5-Step Checklist: How to Prepare Your Portfolio for Volatility."

Don't miss out on this opportunity for peace of mind. Just click below to learn how to receive your complimentary report today!

Get Our Free Report Today

More on Investing

Investor wonders if it's safe to buy stocks now
Bank Stocks

Where Will Royal Bank of Canada Be in 2 Years?

Down 12% from all-time highs, RBC stock trades at a sizeable discount to consensus price target estimates in April 2025.

Read more »

protect, safe, trust
Dividend Stocks

How I’d Allocate $1,000 in Defensive Stocks in Today’s Market

These defensive stocks are outperforming the broader market despite economic uncertainty, providing stability, income, and growth.

Read more »

Piggy bank and Canadian coins
Dividend Stocks

Where I’d Invest My Savings in the TSX Today

These two TSX stocks would be my first picks if I were putting more money into the stock market today.

Read more »

Paper Canadian currency of various denominations
Dividend Stocks

How I’d Adjust My Portfolio to Benefit from Canadian Dollar Movements

TSX stocks benefit from Canadian dollar movements, although the loonie will be under pressure in 2025 due to trade uncertainty.

Read more »

tsx today
Stock Market

TSX Today: What to Watch for in Stocks on Monday, April 7

With a 6.3% weekly loss, the TSX just posted its steepest percentage decline in a single week since June 2022.

Read more »

Stocks for Beginners

Dip Buyers Could Win Big: The Best Canadian Stocks to Buy Now

These two growth stocks have taken hits recently, but their fundamentals remain strong, and their growth prospects are intact.

Read more »

A bull and bear face off.
Stock Market

Bear Market Bargains Emerge as Recession Stocks Return

If you want a deal, then go to the best stocks during a recession market dip.

Read more »

Canadian Red maple leaves seamless wallpaper pattern
Dividend Stocks

5 Canadian Dividend Stocks to Buy and Hold for the Next 20 Years

These Canadian stocks have paid dividends for decades, making them reliable investments to generate regular passive income.

Read more »